All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Plug Power, the most common co-covered peer. The tracked stories average 4 original sources each. STAAR Surgical appears in 1 tracked Biotech story from March 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about STAAR Surgical
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Plug Power, the most common co-covered peer. The tracked stories average 4 original sources each. STAAR Surgical appears in 1 tracked Biotech story from March 4, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering STAAR Surgical. Shared-story counts are live from our verified record — not editorial picks.
STAAR Surgical reported a narrowed net loss for the fourth quarter, signaling operational efficiency and steady demand for its EVO ICL lens technology. The results highlight the company's resilience in the premium refractive surgery market despite broader macroeconomic headwinds in key Asian markets.
STAAR Surgical is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.